blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2255801

EP2255801 - Pharmaceutically active isoindoline derivatives [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  14.12.2012
Database last updated on 16.11.2024
Most recent event   Tooltip18.04.2014Lapse of the patent in a contracting state
New state(s): TR		published on 21.05.2014  [2014/21]
Applicant(s)For all designated states
Celgene Corporation
86 Morris Avenue Summit
New Jersey 07901 / US
[N/P]
Former [2010/48]For all designated states
CELGENE CORPORATION
86 Morris Avenue Summit
New Jersey 07901 / US
Inventor(s)01 / Man, Hon-Wah
27 Grant Way
Princeton, NJ 08540 / US
02 / Muller, George W.
P.O. Box 3688
Rancho Santa Fe, CA 92067 / US
 [2011/14]
Representative(s)Ritter, Thomas Kurt, et al
Jones Day
Prinzregentenstraße 11
80538 München / DE
[2012/06]
Former [2010/48]Ritter, Thomas Kurt, et al
Jones Day Prinzregentenstraße 11
80538 München / DE
Application number, filing date10176390.209.11.2000
[2010/48]
Priority number, dateUS19990165168P12.11.1999         Original published format: US 165168 P
US2000059034408.06.2000         Original published format: US 590344
US2000070819908.11.2000         Original published format: US 708199
[2010/48]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report 
No.:EP2255801
Date:01.12.2010
Language:EN
[2010/48]
Type: B1 Patent specification 
No.:EP2255801
Date:08.02.2012
Language:EN
[2012/06]
Search report(s)(Supplementary) European search report - dispatched on:EP28.10.2010
ClassificationIPC:A61K31/4035, C07D209/46, C07D209/48, C07D403/04, C07D403/06, A61P11/06, A61P29/00, A61P35/00, A61P35/02, A61P37/06
[2010/48]
CPC:
C07D209/48 (EP,US); A61P1/00 (EP); A61P11/00 (EP);
A61P11/06 (EP); A61P11/08 (EP); A61P19/02 (EP);
A61P29/00 (EP); A61P31/18 (EP); A61P31/22 (EP);
A61P35/00 (EP); A61P35/02 (EP); A61P37/00 (EP);
A61P37/06 (EP); A61P43/00 (EP); C07D209/46 (EP,US);
C07D413/04 (EP,US); C07D471/04 (EP,US); C07D487/04 (EP,US) (-)
Designated contracting statesAT,   BE,   CH,   CY,   DE,   DK,   ES,   FI,   FR,   GB,   GR,   IE,   IT,   LI,   LU,   MC,   NL,   PT,   SE,   TR [2010/48]
Extension statesAL27.05.2011
LT27.05.2011
LV27.05.2011
MK27.05.2011
RO27.05.2011
SI27.05.2011
TitleGerman:Pharmazeutisch aktive Isoindolin-Derivate[2010/48]
English:Pharmaceutically active isoindoline derivatives[2010/48]
French:Dérivés d'isoindoline pharmaceutiquement actifs[2010/48]
Examination procedure27.05.2011Amendment by applicant (claims and/or description)
27.05.2011Examination requested  [2011/27]
13.09.2011Communication of intention to grant the patent
22.12.2011Fee for grant paid
22.12.2011Fee for publishing/printing paid
Parent application(s)   TooltipEP00977095.9  / EP1228071
EP06009632.8  / EP1698334
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued (EP20000977095) is  24.03.2003
Opposition(s)09.11.2012No opposition filed within time limit [2013/03]
Fees paidRenewal fee
13.09.2010Renewal fee patent year 03
13.09.2010Renewal fee patent year 04
13.09.2010Renewal fee patent year 05
13.09.2010Renewal fee patent year 06
13.09.2010Renewal fee patent year 07
13.09.2010Renewal fee patent year 08
13.09.2010Renewal fee patent year 09
13.09.2010Renewal fee patent year 10
24.11.2010Renewal fee patent year 11
23.11.2011Renewal fee patent year 12
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipAT08.02.2012
BE08.02.2012
CY08.02.2012
DK08.02.2012
FI08.02.2012
NL08.02.2012
SE08.02.2012
TR08.02.2012
GR09.05.2012
PT08.06.2012
[2014/21]
Former [2013/07]AT08.02.2012
BE08.02.2012
CY08.02.2012
DK08.02.2012
FI08.02.2012
NL08.02.2012
SE08.02.2012
GR09.05.2012
PT08.06.2012
Former [2012/49]BE08.02.2012
CY08.02.2012
DK08.02.2012
FI08.02.2012
NL08.02.2012
SE08.02.2012
GR09.05.2012
PT08.06.2012
Former [2012/48]BE08.02.2012
CY08.02.2012
FI08.02.2012
NL08.02.2012
SE08.02.2012
GR09.05.2012
PT08.06.2012
Former [2012/41]BE08.02.2012
CY08.02.2012
FI08.02.2012
NL08.02.2012
GR09.05.2012
PT08.06.2012
Former [2012/37]BE08.02.2012
FI08.02.2012
NL08.02.2012
GR09.05.2012
PT08.06.2012
Former [2012/36]NL08.02.2012
GR09.05.2012
Former [2012/35]NL08.02.2012
Documents cited:Search[A]WO9501348  (CELGENE CORP [US], et al) [A] 1-6 * the entire document *;
 [A]WO9620926  (CELGENE CORP [US], et al) [A] 1-6* the entire document *;
 [A]WO9708143  (CELGENE CORP [US], et al) [A] 1-6 * the entire document *;
 [A]WO9723457  (CELGENE CORP [US], et al) [A] 1-6 * the entire document *;
 [A]WO9824763  (CELGENE CORP [US], et al) [A] 1-6 * page 10, lines 3,5,7,9, page 11, lines 3,5,7,9, Example 15 *;
 [A]WO9906041  (CELGENE CORP [US], et al) [A] 1-6 * the entire document *;
 [AP]WO0025777  (CELGENE CORP [US]) [AP] 1-6 * page 19, Example 3, page 23, Example 9, page 12, Example 12, page 27, Example 15 *
by applicant   - TRACEY ET AL., NATURE, (1987), vol. 330, pages 662 - 664
    - HINSHAW ET AL., CIRC. SHOCK, (1990), vol. 30, pages 279 - 292
    - DEZUBE ET AL., LANCET, (1990), vol. 335, no. 8690, page 662
    - MILLAR ET AL., LANCET, (1989), vol. 2, no. 8665, pages 712 - 714
    - FER- RAI-BALIVIERA ET AL., ARCH. SURG., (1989), vol. 124, no. 12, pages 1400 - 1405
    - BERTOLINI ET AL., NATURE, (1986), vol. 319, pages 516 - 518
    - JOHNSON ET AL., ENDOCRINOLOGY, (1989), vol. 124, no. 3, pages 1424 - 1427
    - CALCI. TISSUE INT. (US), (1990), vol. 46, pages 3 - 10
    - HOLLER ET AL., BLOOD, (1990), vol. 75, no. 4, pages 1011 - 1016
    - GRAU ET AL., N. ENGL. J. MED., (1989), vol. 320, no. 24, pages 1586 - 1591
    - MOSES ET AL., BIOTECH., (1991), vol. 9, pages 630 - 634
    - FOLKMAN ET AL., N. ENGL. J. MED., (1995), vol. 333, pages 1757 - 1763
    - AUERBACH ET AL., J. MICROVASC. RES., (1985), vol. 29, pages 401 - 411
    - FOLKMAN, Advances in Cancer Research, ACADEMIC PRESS, (1985), pages 175 - 203
    - PATZ, AM. J. OP- THALMOL., (1982), vol. 94, pages 715 - 743
    - FOLKMAN ET AL., SCIENCE, (1983), vol. 221, pages 719 - 725
    - FOLKMAN; KLAGSBRUN, SCIENCE, (1987), vol. 235, pages 442 - 447
    - WALTMAN ET AL., AM. J. OPHTHAL., (1978), vol. 85, pages 704 - 710
    - GARTNER ET AL., SURV. OPHTHAL., (1978), vol. 22, pages 291 - 312
    - RASTINEJAD ET AL., CELL, (1989), vol. 56, pages 345 - 355
    - LEIBOVICH ET AL., NATURE, (1987), vol. 329, pages 630 - 632
    - CHING ET AL., BRIT. J. CANCER, (1955), vol. 72, pages 339 - 343
    - KOCH, PROGRESS IN MEDICINAL CHEMISTRY, (1985), vol. 22, pages 166 - 242
    - PIGNET ET AL., NATURE, (1990), vol. 344, pages 245 - 247
    - BISSONNETTE ET AL., INFLAMMATION, (1989), vol. 13, no. 3, pages 329 - 339
    - BAUGHMAN ET AL., J. LAB. CLIN. MED., (1990), vol. 115, no. I, pages 36 - 42
    - VEDDER ET AL., PNAS, (1990), vol. 87, pages 2643 - 2646
    - SHERRY ET AL., J. CELL BIOL., (1988), vol. 107, pages 1269 - 1277
    - MUNRO ET AL., AM. J PATH., (1989), vol. 135, pages 121 - 132
    - ELLIOT, INT. J. PHARMAC., (1995), vol. 17, no. 2, pages 141 - 145
    - VON DULLEMEN ET AL., GASTROENTEROLOGY, (1995), vol. 109, no. !, pages 129 - 135
    - DUH ET AL., PROC. NAT. ACAD. SCI., (1989), vol. 86, pages 5974 - 5978
    - POLL ET AL., PROC. NAT. ACAD. SCI., (1990), vol. 87, pages 782 - 785
    - MONTO ET AL., BLOOD, (1990), vol. 79, page 2670
    - CLOUSE ET AL., J. IMMUNOL., (1989), vol. 142, pages 431 - 438
    - POLL ET AL., AIDS RES. HUM. RETROVIRUS, (1992), pages 191 - 197
    - ROSENBERG ET AL., "The Immunopathogenesis of HIV Infection", ADVANCES IN IMMUNOLOGY, (1989), vol. 57
    - POLI ET AL., PROC. NATL. ACAD. SCI., (1990), vol. 87, pages 782 - 784
    - OSBOM ET AL., PNAS, vol. 86, pages 2336 - 2340
    - FOLKS ET AL., PNAS, (1989), vol. 86, pages 2365 - 2368
    - OSBORN ET AL., PNAS, (1989), vol. 86, pages 2336 - 2340
    - WRIGHT ET AL., J. IMMUNOL., (1988), vol. 141, no. 1, pages 99 - 104
    - LENARDO ET AL., CELL, (1989), vol. 58, pages 227 - 29
    - DBAIBO ET AL., J BIOL. CHEM., (1993), pages 17762 - 66
    - DUH ET AL., PROC. NATL. ACAD. SCI., (1989), vol. 86, pages 5974 - 78
    - BACHELERIE ET AL., NATURE, (1991), vol. 350, pages 709 - 12
    - BOSWAS ET AL., J ACQUIRED IMMUNE DEFICIENCY SYNDROME, (1993), vol. 6, pages 778 - 786
    - SUZUKI ET AL., BIOCHEM. AND BIOPHYS. RES. COMM., (1993), vol. 193, pages 277 - 83
    - SUZUKI ET AL., BIOCHEM. AND BIOPHYS. RES. COMM., (1992), vol. 189, pages 1709 - 15
    - SUZUKI ET AL., BIOCHEM. MOL. BIO. INT., (1993), vol. 31, no. 4, pages 693 - 700
    - SHAKHOV ET AL., PROC. NATL. ACAD. SCI. USA, (1990), vol. 171, pages 35 - 47
    - STAAL ET AL., PROC. NATL. ACAD. SCI. USA, (1990), vol. 87, pages 9943 - 47
    - LOWE; CHENG, DRUGS OF THE FUTURE, (1992), vol. 17, no. 9, pages 799 - 807
    - BEAVO; REITSNYDER, TRENDS IN PHARM., (1990), vol. 11, pages 150 - 155
    - VERGHESE ET AL., JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, (1995), vol. 272, no. 3, pages 1313 - 1320
    - SCHRODER; LUBKE, The Peptides, ACADEMIC PRESS, (1965), vol. I
    - HOUBEN-WEYL, Methoden der organischen Chemie, 4th Edition,, GEORG THIEME VERLAG, (1974), vol. 15IL
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.